Skip to content
OpenCapital
Get started

Organogenesis Holdings Inc. ORGO Product — Revenue

Other product segments

Grant
$978K—

Similar metrics at other companies

TransMedics Group, Inc. logo
TMDXProduct — Revenue
$107.97M+22.4%
ClearPoint Neuro logo
CLPTProduct — Revenue
$8.8M+66.4%
CryoPort, Inc. logo
CYRXProduct — Revenue
$20.9M+15.0%
Red Cat Holdings, Inc. logo
RCATProduct — Revenue
$15.21M+833%
Seaboard logo
SEBProduct — Revenue
$1.88B+2.5%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×—
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%—
Net margin0.5%+0.3pp
FCF margin6.9%—

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s product — revenue?
Organogenesis Holdings Inc. (ORGO) reported product — revenue of $36.25M in Q1 2026.
How has Organogenesis Holdings Inc.'s product — revenue changed year-over-year?
Organogenesis Holdings Inc.'s product — revenue decreased by 58.2% year-over-year, from $86.69M to $36.25M.
What is the long-term trend for Organogenesis Holdings Inc.'s product — revenue?
Over 2 years (2023 to 2025), Organogenesis Holdings Inc.'s product — revenue has grown at a 14.0% compound annual growth rate (CAGR), from $433.14M to $563.03M.
What does product — revenue mean?
This metric represents the total gross sales generated from the company's core regenerative medicine product portfolio, including advanced wound care and surgical and sports medicine solutions. It serves as a primary indicator of market adoption and commercial success for the company's proprietary medical technologies. Tracking this revenue stream provides insight into the company's ability to scale its core product offerings within the healthcare sector.